Expertgroup Life Science and Biotechnology
Business plan 2004-2005
Trends and needs
Out of the about 2000 European companies that apply modern biotechnology, more than 20% are in the Nordic Countries. Although this branch of industry is still young and developing, its significance for our future industrial and technological success is widely recognized.
In its communication (23.1.2002) “Life sciences and biotechnology – a strategy for Europe” the EU Commission emphasizes several short- and long-term regulatory actions together with implementation and enforcement activities. Among those are e.g., traceability of food and feed derivatives from genetically modified organisms, guidance for detection and sampling methodology, development of methodologies for monitoring potential long-term environmental impacts of GMO´s, and methodologies for the monitoring of effects of genetically modified food and feed as compared with conventional food and feed.
The emergence of new technologies, and consecutively new therapeutic methods require adequate legislation and regulation. The Nordic Countries are in the forefront of this particular research area, so the evaluation and adoption of best practises used in the different Nordic Countries can be exploited to generate and create a coherent basis for the legislation and regulations concerning the therapeutic use of stem cells and for the usage of data from the human genome map.
Activity area within innovation, development of best practise and Conformity Assessment (CA)
Based on the above trends and needs the expert group Life Science and Biotechnology has pinpointed the following important, prioritised activity areas
Trends and needs
Out of the about 2000 European companies that apply modern biotechnology, more than 20% are in the Nordic Countries. Although this branch of industry is still young and developing, its significance for our future industrial and technological success is widely recognized.
In its communication (23.1.2002) “Life sciences and biotechnology – a strategy for Europe” the EU Commission emphasizes several short- and long-term regulatory actions together with implementation and enforcement activities. Among those are e.g., traceability of food and feed derivatives from genetically modified organisms, guidance for detection and sampling methodology, development of methodologies for monitoring potential long-term environmental impacts of GMO´s, and methodologies for the monitoring of effects of genetically modified food and feed as compared with conventional food and feed.
The emergence of new technologies, and consecutively new therapeutic methods require adequate legislation and regulation. The Nordic Countries are in the forefront of this particular research area, so the evaluation and adoption of best practises used in the different Nordic Countries can be exploited to generate and create a coherent basis for the legislation and regulations concerning the therapeutic use of stem cells and for the usage of data from the human genome map.
Activity area within innovation, development of best practise and Conformity Assessment (CA)
Based on the above trends and needs the expert group Life Science and Biotechnology has pinpointed the following important, prioritised activity areas
- New methods for sampling, detection, monitoring and quantification of zoonose diseases, GMO, allergenes and functional ingredients and additives.
- New methods and processes for removal of organic pollution materials and chemicals and new methods for risk identification and -assessment concerning application of genetically modified organisms in the Nordic and Baltic environment.
- Exploitation and evaluation of the best practises in the therapeutic use of adult and embryonic stem cells in order to generate and create a coherent basis for the legislation and regulations concerning their therapeutic use in the EU.
- Exploitation of the best practises in the use of database of human genetic material in the evaluation of hereditary diseases and risk factors for common metabolic disorders.
Project list
The list is giving examples of projects that the Life Science-group is considering as important.
The list is giving examples of projects that the Life Science-group is considering as important.
- A project leading to a position paper concerning the best practises in the therapeutic use of adult and embryonic stem cells.
- A project investigating the present situation in best practises in the use of countrywide database of human genetic material in the evaluation of hereditary diseases and risk factors for common metabolic disorders and a possible arrangement of a workshop to discuss the issue with the interested Nordic and baltic parties
- Project dealing with new methods for risk identification and -assessment concerning application of genetically modified organisms in the Nordic and Baltic environment.
- Projects dealing with new methods for sampling, detection, monitoring and quantification of zoonose diseases, GMO, allergenes and functional ingredients and additives.
Updated 2004-06-24
Kontaktpersoner:
DENMARK
Lars Chr. Nielsen
Bolander Innovation
Alpevej 7
DK-7120 Vejle Ø
FINLAND
VD Kaj Falk
FRH Technology Partnership Oy
Jungfrustigen 2b A 15-16
FIN-00140 Helsingfors
ICELAND
M.Sc. Solveig K. Petursdóttir
Prokaria ltd.
Gylfaflöt 5
IS-112 Reykjavík
NORWAY
Dr. Arne Holst-Jensen
Section of Feed and Food Microbiology
National Veterinary Institute
Ullevaalsveien 68
P.O. Box 8156 Dep.
NO-0033 Oslo
SWEDEN
Gustaf Brunius
Gentekniknämnden
Retzius väg 13A
SE-171 77 Stockholm
Kontaktpersoner:
DENMARK
Lars Chr. Nielsen
Bolander Innovation
Alpevej 7
DK-7120 Vejle Ø
FINLAND
VD Kaj Falk
FRH Technology Partnership Oy
Jungfrustigen 2b A 15-16
FIN-00140 Helsingfors
ICELAND
M.Sc. Solveig K. Petursdóttir
Prokaria ltd.
Gylfaflöt 5
IS-112 Reykjavík
NORWAY
Dr. Arne Holst-Jensen
Section of Feed and Food Microbiology
National Veterinary Institute
Ullevaalsveien 68
P.O. Box 8156 Dep.
NO-0033 Oslo
SWEDEN
Gustaf Brunius
Gentekniknämnden
Retzius väg 13A
SE-171 77 Stockholm
Printervennlig versjon
